ECSP21042554A - Proteínas f de prefusión del vrs estabilizadas - Google Patents

Proteínas f de prefusión del vrs estabilizadas

Info

Publication number
ECSP21042554A
ECSP21042554A ECSENADI202142554A ECDI202142554A ECSP21042554A EC SP21042554 A ECSP21042554 A EC SP21042554A EC SENADI202142554 A ECSENADI202142554 A EC SENADI202142554A EC DI202142554 A ECDI202142554 A EC DI202142554A EC SP21042554 A ECSP21042554 A EC SP21042554A
Authority
EC
Ecuador
Prior art keywords
proteins
stabilized rsv
rsv prefusion
prefusion
stabilized
Prior art date
Application number
ECSENADI202142554A
Other languages
English (en)
Inventor
Johannes Langedijk
Original Assignee
Janssen Vaccines Prevention B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines Prevention B V filed Critical Janssen Vaccines Prevention B V
Publication of ECSP21042554A publication Critical patent/ECSP21042554A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona proteínas F de prefusión del virus respiratorio sincitial (VRS) estables, composiciones inmunógenas que comprenden dichas proteínas y usos de estas para la prevención y/o el tratamiento de una infección por VRS.
ECSENADI202142554A 2018-11-13 2021-06-11 Proteínas f de prefusión del vrs estabilizadas ECSP21042554A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18205863 2018-11-13

Publications (1)

Publication Number Publication Date
ECSP21042554A true ECSP21042554A (es) 2021-11-30

Family

ID=64308587

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202142554A ECSP21042554A (es) 2018-11-13 2021-06-11 Proteínas f de prefusión del vrs estabilizadas

Country Status (19)

Country Link
US (1) US20220017574A1 (es)
EP (1) EP3880243A1 (es)
JP (1) JP2022513025A (es)
KR (1) KR20210091749A (es)
CN (1) CN113164583A (es)
AU (1) AU2019377989A1 (es)
BR (1) BR112021008975A2 (es)
CA (1) CA3117275A1 (es)
CL (1) CL2021001212A1 (es)
CO (1) CO2021006308A2 (es)
CR (1) CR20210306A (es)
EA (1) EA202191355A1 (es)
EC (1) ECSP21042554A (es)
IL (1) IL282892A (es)
JO (1) JOP20210106A1 (es)
MX (1) MX2021005607A (es)
PE (1) PE20211469A1 (es)
SG (1) SG11202104522UA (es)
WO (1) WO2020099383A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102638978B1 (ko) 2015-07-07 2024-02-22 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
CA3018139A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
KR102421049B1 (ko) 2016-05-30 2022-07-15 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합-전 rsv f 단백질
CA3211034A1 (en) * 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
KR20230047033A (ko) * 2021-09-29 2023-04-06 에스케이바이오사이언스(주) 재조합된 약독화 rsv 생백신 및 이를 제조하는 방법
CN115850396B (zh) * 2022-12-22 2024-02-06 北京吉诺卫生物科技有限公司 一种rsv纳米颗粒疫苗及其制备方法与应用
WO2024175579A1 (en) 2023-02-21 2024-08-29 Janssen Vaccines & Prevention B.V. Stabilized trimeric rsv fusion proteins without a heterologous trimerzation domain
CN117304280B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用
CN117304279B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用
CN117777251B (zh) * 2024-02-27 2024-06-04 普大生物科技(泰州)有限公司 一种rsv纳米颗粒疫苗及其制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
EP2164860A2 (en) * 2007-06-06 2010-03-24 Nationwide Children's Hospital, Inc. Methods and compositions relating to viral fusion proteins
EP4206231A1 (en) 2007-12-24 2023-07-05 ID Biomedical Corporation of Quebec Recombinant rsv antigens
WO2010149745A1 (en) 2009-06-24 2010-12-29 Glaxosmithkline Biologicals S.A. Recombinant rsv antigens
MX2012000036A (es) 2009-06-24 2012-02-28 Glaxosmithkline Biolog Sa Vacuna.
IN2012DN01328A (es) * 2009-08-13 2015-06-05 Crucell Holland Bv
CN103097412B (zh) 2010-07-09 2016-08-10 克鲁塞尔荷兰公司 抗人呼吸道合胞病毒(rsv)抗体以及使用方法
PL2707385T3 (pl) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Prefuzyjne antygeny RSV F
WO2014160463A1 (en) * 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prefusion rsv f proteins and their use
AU2014239583B2 (en) * 2013-03-14 2020-07-02 Children's Healthcare Of Atlanta, Inc. Recombinant RSV with silent mutations, vaccines, and methods related thereto
PL2988780T3 (pl) * 2013-04-25 2019-06-28 Janssen Vaccines & Prevention B.V. Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSV
WO2014202570A1 (en) * 2013-06-17 2014-12-24 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
WO2016040556A1 (en) * 2014-09-12 2016-03-17 Rsv Corporation Virosomes containing respiratory syncytial virus strain line 19 fusion protein and uses thereof
KR102638978B1 (ko) * 2015-07-07 2024-02-22 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
US10457708B2 (en) * 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
EP3368547A4 (en) * 2015-10-29 2019-06-05 Emory University RSV CHIMERIC VIRUSES, IMMUNOGENIC COMPOSITIONS AND METHODS OF USE
RU2723039C2 (ru) * 2015-12-23 2020-06-08 Пфайзер Инк. Мутанты белка f rsv
AU2017242020B2 (en) * 2016-03-29 2021-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion RSV F proteins and their use
KR102506895B1 (ko) 2016-04-05 2023-03-08 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 용해성 융합-전 rsv f 단백질
KR102421049B1 (ko) * 2016-05-30 2022-07-15 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합-전 rsv f 단백질

Also Published As

Publication number Publication date
WO2020099383A1 (en) 2020-05-22
EA202191355A1 (ru) 2021-09-20
CO2021006308A2 (es) 2021-05-31
PE20211469A1 (es) 2021-08-05
CN113164583A (zh) 2021-07-23
CL2021001212A1 (es) 2021-10-22
MX2021005607A (es) 2021-06-30
SG11202104522UA (en) 2021-05-28
CR20210306A (es) 2021-07-22
CA3117275A1 (en) 2020-05-22
JP2022513025A (ja) 2022-02-07
BR112021008975A2 (pt) 2021-08-17
IL282892A (en) 2021-06-30
KR20210091749A (ko) 2021-07-22
US20220017574A1 (en) 2022-01-20
EP3880243A1 (en) 2021-09-22
AU2019377989A1 (en) 2023-10-05
JOP20210106A1 (ar) 2023-01-30

Similar Documents

Publication Publication Date Title
ECSP21042554A (es) Proteínas f de prefusión del vrs estabilizadas
CL2018002826A1 (es) Proteínas f de prefusión del virus respiratorio sincicial (vrs) solubles y estabilizadas
CY1121600T1 (el) Σταθεροποιημενα διαλυτα πολυπεπτιδια rsv f προσυντηξης
BR112017028449A2 (pt) polipeptídeos rsv f pré-fusão solúveis estabilizados
CL2018003383A1 (es) Proteínas f de prefusión del vrs estabilizadas.
CY1125329T1 (el) Αντιιικες ενωσεις πυραζολο- και τριαζολο-πυριμιδινης εναντι toy rsv
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
PH12015502735B1 (en) Stabilized soluble pre-fusion rsv f polypeptides
CL2019003309A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2019002745A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2019002744A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2019003294A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
DOP2021000111A (es) 3,3- difluoroalilaminas o sales de las mismas y composiciones farmacéuticas que las comprenden
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CL2017003260A1 (es) Dominios variables simples de inmunoglobulina contra proteína f de rsv.
CL2020001353A1 (es) Pirazolopirimidinas que tienen actividad contra el vsr.